Personal CFO Solutions LLC Sells 28,729 Shares of Merck & Co., Inc. $MRK

by · The Cerbat Gem

Personal CFO Solutions LLC cut its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 53.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,093 shares of the company’s stock after selling 28,729 shares during the period. Personal CFO Solutions LLC’s holdings in Merck & Co., Inc. were worth $1,986,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Little House Capital LLC raised its holdings in Merck & Co., Inc. by 1.2% during the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after acquiring an additional 308 shares in the last quarter. Semus Wealth Partners LLC grew its stake in Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after purchasing an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC increased its position in shares of Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after purchasing an additional 3,282 shares during the last quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH increased its position in shares of Merck & Co., Inc. by 9.8% during the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after purchasing an additional 79,529 shares during the last quarter. Finally, Amplius Wealth Advisors LLC raised its stake in shares of Merck & Co., Inc. by 117.4% during the 2nd quarter. Amplius Wealth Advisors LLC now owns 6,165 shares of the company’s stock worth $488,000 after purchasing an additional 3,329 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

MRK has been the subject of several recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Citigroup started coverage on shares of Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Merck & Co., Inc. from $110.00 to $111.00 and gave the stock a “hold” rating in a research note on Tuesday. Finally, Wells Fargo & Company dropped their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Hold” and a consensus price target of $104.88.

Check Out Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 0.0%

MRK stock opened at $95.00 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The company has a fifty day moving average price of $86.09 and a two-hundred day moving average price of $82.70. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $105.07. The stock has a market cap of $235.80 billion, a price-to-earnings ratio of 14.64, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.36 by $0.22. The company had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company’s revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.57 earnings per share. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Shareholders of record on Monday, December 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.40 annualized dividend and a yield of 3.6%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.81. Merck & Co., Inc.’s payout ratio is currently 42.80%.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the sale, the executive vice president directly owned 24,578 shares in the company, valued at $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.13% of the stock is owned by company insiders.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).